Navigation Links
Chromos enters into loan and lending arrangements
Date:3/20/2008

BURNABY, BC, March 20 /PRNewswire-FirstCall/ - Chromos Molecular Systems Inc. ("Chromos") (TSX:CHR) announced today that the Company entered into a secured, convertible debenture agreement to borrow $400,000. The proceeds of the loan are to be used to fund expenses associated with the preparation of delinquent continuous disclosure documents and maintaining the integrity of the remaining assets of the Company. The principal and interest, at 12% per annum, are due and payable on June 30, 2008. The debenture holder has the right, upon notice, to convert all or part of the principal and unpaid interest into common shares of the Company at the conversion price of $0.03 per share. The Company also entered into a Pledge of Securities agreement as part of the security arrangement with the debenture holder for the Company's common shares in Agrisoma Biosciences Inc. ("Agrisoma"). As collateral for the convertible debenture, the Company provided the debenture holder a general security agreement providing a charge over all the Company's assets. Prior to entering into this transaction, the Company obtained a partial revocation of the existing cease trade order from the B.C. Securities Commission.

The Company has also entered into a convertible promissory note agreement (the "Agrisoma Note") to loan $500,000 to Agrisoma. Of this amount, $118,000 was funded in-kind by Chromos by offsetting it against $118,000 of amounts due from Agrisoma for license fees, rent and other services, and patent cost recoveries. The remaining $382,000 was funded in cash by Chromos to Agrisoma. The cash advanced to Agrisoma is to be used for operations. The secured Agrisoma Note, which bears interest of 15% per annum, is due the earlier of: June 30, 2008 and certain specified events. As collateral for the Agrisoma Note, Agrisoma provided the Company with a general security agreement providing a charge over all of Agrisoma's assets.

Risks and Uncertainties

Certain of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Chromos, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

To the extent possible, management implements strategies to reduce or mitigate the risks and uncertainties associated with Chromos' operations. Operating risks include (i) the continued availability of capital to finance Chromos' activities; (ii) Chromos' limited cash position, and (iii) Chromos' limited operations.

CONTACT: Jeff Charpentier, Vice President, Finance and CFO, Tel: (604) 415-7132, Email:jcharpentier@chromos.com; Alistair Duncan, President & CEO, Tel: (604) 415-7121, Email: aduncan@chromos.com, Website: http://www.chromos.com


'/>"/>
SOURCE Chromos Molecular Systems Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
2. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
3. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
4. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
5. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
6. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
7. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
8. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
9. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
10. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
11. Sangui Partnership Enters a New Phase:
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... 2017  This year,s edition of the Inc. 5000 features a now-familiar ... solutions, has made the list for the third year in a row. ... private companies based on a set of quantitative metrics. In addition, BioPoint ... companies in the Bay State . ... Inc. 5000 ...
(Date:8/15/2017)... After spending the past two years building a state-of-the-art ... GeneFo now offers this platform to healthcare stakeholders (hospitals, foundations, biopharma ... and data collection vis a vis their members, under their own ... of this offer. ... ...
(Date:8/15/2017)... CA (PRWEB) , ... August 15, 2017 , ... ... pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of ... number of steps needed to gain kinetic binding data for a wide range ...
(Date:8/15/2017)... ... 2017 , ... Any expert in stem cell research or stem cell medicine ... half a century. Despite their essential roles in human health and regenerative medicine, ... tags developed for this purpose also tag other, more abundant, non-stem tissue cells ( ...
Breaking Biology Technology:
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
Breaking Biology News(10 mins):